Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations

References

1. • Reyes-Soffer G.
   • Ginsberg H.N.
   • Berglund L.
   • Duell P.B.
   • Heffron S.P.
   • Kamstrup P.R.
   • et al.
   Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association.
   Arterioscler Thromb Vasc Biol. 2022; 42: e48-e60
   View in Article

   • Google Scholar
2. • Kronenberg F.
   • Mora S.
   • Stroes E.S.G.
   • Ference B.A.
   • Arsenault B.J.
   • Berglund L.
   • et al.
   Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
   Eur Heart J. 2022; 43: 3925-3946
   View in Article

   • Google Scholar
3. • Weisel J.W.
   • Nagaswami C.
   • Woodhead J.L.
   • Higazi A.A.
   • Cain W.J.
   • Marcovina S.M.
   • et al.
   The structure of lipoprotein(a) and ligand-induced conformational changes.
   Biochemistry. 2001; 40: 10424-10435
   View in Article

   • Google Scholar
4. • Boffa M.B.
   • Koschinsky M.L.
   Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.
   Nat Rev Cardiol. 2019; 16: 305-318
   View in Article

   • Google Scholar
5. • Ward N.C.
   • Kostner K.M.
   • Sullivan D.R.
   • Nestel P.
   • Watts G.F.
   Molecular, population, and clinical aspects of lipoprotein(a): a bridge too far?.
   J Clin Med. 2019; 8: 2073
   View in Article

   • Google Scholar
6. • Nordestgaard B.G.
   • Langsted A.
   Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
   J Lipid Res. 2016; 57: 1953-1975
   View in Article

   • Google Scholar
7. • Patel A.P.
   • Wang M.
   • Pirruccello J.P.
   • Ellinor P.T.
   • Ng K.
   • Kathiresan S.
   • et al.
   Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank.
   Arterioscler Thromb Vasc Biol. 2021; 41: 465-474
   View in Article

   • Google Scholar
8. • Ward N.C.
   • Vickneswaran S.
   • Watts G.F.
   Lipoprotein(a) and diabetes mellitus: causes and consequences.
   Curr Opin Endocrinol Diabetes Obes. 2021; 28: 181-187
   View in Article

   • Google Scholar
9. • Mehta A.
   • Vasquez N.
   • Ayers C.R.
   • Patel J.
   • Hooda A.
   • Khera A.
   • et al.
   Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk.
   J Am Coll Cardiol. 2022; 79: 757-768
   View in Article

   • Google Scholar
10. • Duarte Lau F.
    • Giugliano R.P.
    Lipoprotein(a) and its significance in cardiovascular disease: a review.
    JAMA Cardiol. 2022; 7: 760-769
    View in Article

    • Google Scholar
11. • Nestel P.J.
    • Barnes E.H.
    • Tonkin A.M.
    • Simes J.
    • Fournier M.
    • White H.D.
    • et al.
    Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
    Arterioscler Thromb Vasc Biol. 2013; 33: 2902-2908
    View in Article

    • Google Scholar
12. • Marcovina S.M.
    • Clouet-Foraison N.
    • Koschinsky M.L.
    • Lowenthal M.S.
    • Orquillas A.
    • Boffa M.B.
    • et al.
    Development of an LC-MS/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a).
    Clin Chem. 2021; 67: 490-499
    View in Article

    • Google Scholar
13. • Marcovina S.M.
    • Navabi N.
    • Allen S.
    • Gonen A.
    • Witztum J.L.
    • Tsimikas S.
    Development and validation of an isoform independent monoclonal antibody-based ELISA for measurement of lipoprotein(a).
    J Lipid Res. 2022; 63100239
    View in Article

    • Google Scholar
14. • Tsimikas S.
    • Moriarty P.M.
    • Stroes E.S.
    Emerging RNA therapeutics to lower blood levels of Lp(a): JACC Focus Seminar 2/4.
    J Am Coll Cardiol. 2021; 77: 1576-1589
    View in Article

    • Google Scholar
15. • Swerdlow D.I.
    • Rider D.A.
    • Yavari A.
    • Wikstrom Lindholm M.
    • Campion G.V.
    • Nissen S.E.
    Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.
    Cardiovasc Res. 2022; 118: 1218-1231
    View in Article

    • Google Scholar
16. • Durlach V.
    • Bonnefont-Rousselot D.
    • Boccara F.
    • Varret M.
    • Di-Filippo Charcosset M.
    • Cariou B.
    • et al.
    2021, Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults.
    Can J Cardiol. 2021; 37: 1129-1150
    View in Article

    • Google Scholar
17. • Pearson G.J.
    • Thanassoulis G.
    • Anderson T.J.
    • Barry A.R.
    • Couture P.
    • Dayan N.
    • et al.
    2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults.
    Can J Cardiol. 2021; 37: 1129-1150
    View in Article

    • Google Scholar
18. • Langlois M.R.
    • Nordestgaard B.G.
    • Langsted A.
    • Chapman M.J.
    • Aakre K.M.
    • Baum H.
    • et al.
    European Atherosclerosis Society (EAS), and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.
    Clin Chem Lab Med. 2020; 58: 496-517
    View in Article

    • Google Scholar
19. • Wilson D.P.
    • Jacobson T.A.
    • Jones P.H.
    • Koschinsky M.L.
    • McNeal C.J.
    • Nordestgaard B.G.
    • et al.
    Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association.
    J Clin Lipidol. 2019; 13: 374-392
    View in Article

    • Google Scholar
20. • Cegla J.
    • Neely R.D.G.
    • France M.
    • Ferns G.
    • Byrne C.D.
    • Halcox J.
    • et al.
    HEART UK consensus statement on lipoprotein(a): a call to action.
    Atherosclerosis. 2019; 291: 62-70
    View in Article

    • Google Scholar
21. • Grundy S.M.
    • Stone N.J.
    • Bailey A.L.
    • Beam C.
    • Birtcher K.K.
    • Blumenthal R.S.
    • et al.
    2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.
    Circulation. 2019; 139: e1082-e1143
    View in Article

    • Google Scholar
22. • Mach F.
    • Baigent C.
    • Catapano A.L.
    • Koskinas K.C.
    • Casula M.
    • Badimon L.
    • et al.
    2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
    Eur Heart J. 2020; 41: 111-188
    View in Article

    • Google Scholar
23. • Berman A.N.
    • Biery D.W.
    • Singh A.
    • Wu W.Y.
    • Divakaran S.
    • DeFilippis E.M.
    • et al.
    Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry.
    Eur J Prev Cardiol. 2021; 28: e12-e14
    View in Article

    • Google Scholar
24. • Perrot N.
    • Verbeek R.
    • Sandhu M.
    • Boekholdt S.M.
    • Hovingh G.K.
    • Wareham N.J.
    • et al.
    Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study.
    Atherosclerosis. 2017; 256: 47-52
    View in Article

    • Google Scholar
25. • Khera A.V.
    • Everett B.M.
    • Caulfield M.P.
    • Hantash F.M.
    • Wohlgemuth J.
    • Ridker P.M.
    • et al.
    Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
    Circulation. 2014; 129: 635-642
    View in Article

    • Google Scholar
26. • Albers J.J.
    • Slee A.
    • O'Brien K.D.
    • Robinson J.G.
    • Kashyap M.L.
    • Kwiterovich Jr., P.O.
    • et al.
    Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
    J Am Coll Cardiol. 2013; 62: 1575-1579
    View in Article

    • Google Scholar
27. • Willeit P.
    • Ridker P.M.
    • Nestel P.J.
    • Simes J.
    • Tonkin A.M.
    • Pedersen T.R.
    • et al.
    Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
    Lancet. 2018; 392: 1311-1320
    View in Article

    • Google Scholar
28. • Cho J.H.
    • Lee D.Y.
    • Lee E.S.
    • Kim J.
    • Park S.E.
    • Park C.Y.
    • et al.
    Increased risk of coronary artery calcification progression in subjects with high baseline Lp(a) levels: The Kangbuk Samsung Health Study.
    Int J Cardiol. 2016; 222: 233-237
    View in Article

    • Google Scholar
29. • Zawacki A.W.
    • Dodge A.
    • Woo K.M.
    • Ralphe J.C.
    • Peterson A.L.
    In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
    J Clin Lipidol. 2018; 12: 1445-1451
    View in Article

    • Google Scholar
30. • Gurdasani D.
    • Sjouke B.
    • Tsimikas S.
    • Hovingh G.K.
    • Luben R.N.
    • Wainwright N.W.
    • et al.
    Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.
    Arterioscler Thromb Vasc Biol. 2012; 32: 3058-3065
    View in Article

    • Google Scholar
31. • Verbeek R.
    • Hoogeveen R.M.
    • Langsted A.
    • Stiekema L.C.A.
    • Verweij S.L.
    • Hovingh G.K.
    • et al.
    Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.
    Eur Heart J. 2018; 39: 2589-2596
    View in Article

    • Google Scholar
32. • Cunningham T.E.
    • Sayers S.M.
    • Singh G.R.
    Lipoprotein(a) identifies cardiovascular risk in childhood: the Australian Aboriginal Birth Cohort Study.
    J Paediatr Child Health. 2011; 47: 257-261
    View in Article

    • Google Scholar
33. • Xiong Z.
    • Wahlqvist M.L.
    • Biegler B.
    • Balazs N.D.
    • Buynder P.V.
    • Wattanapenpaiboon N.
    Plasma lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in an Aboriginal population from Western Australia.
    Asia Pac J Clin Nutr. 2000; 9: 235-240
    View in Article

    • Google Scholar
34. • Burgess S.
    • Ference B.A.
    • Staley J.R.
    • Freitag D.F.
    • Mason A.M.
    • Nielsen S.F.
    • et al.
    Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis.
    JAMA Cardiol. 2018; 3: 619-627
    View in Article

    • Google Scholar
35. • Madsen C.M.
    • Kamstrup P.R.
    • Langsted A.
    • Varbo A.
    • Nordestgaard B.G.
    Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study.
    Arterioscler Thromb Vasc Biol. 2020; 40: 255-266
    View in Article

    • Google Scholar
36. • de Boer L.M.
    • Oorthuys A.O.J.
    • Wiegman A.
    • Langendam M.W.
    • Kroon J.
    • Spijker R.
    • et al.
    Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis.
    Eur J Prev Cardiol. 2021; 29: 779-792
    View in Article

    • Google Scholar
37. • Schwartz G.G.
    • Ballantyne C.M.
    Existing and emerging strategies to lower lipoprotein(a).
    Atherosclerosis. 2022; 349: 110-122
    View in Article

    • Google Scholar
38. • Lacaze P.
    • Bakshi A.
    • Riaz M.
    • Polekhina G.
    • Owen A.
    • Bhatia H.S.
    • et al.
    Aspirin for the primary prevention of cardiovascular events in relation to lipoprotein (a) genotypes.
    J Am Col Cardiol. 2022; 80: 1287-1298
    View in Article

    • Google Scholar
39. • Cui K.
    • Wang H.Y.
    • Yin D.
    • Zhu C.
    • Song W.
    • Wang H.
    • et al.
    Benefit and risk of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents in patients with elevated lipoprotein(a) concentrations.
    Front Cardiov Med. 2021; 8807925
    View in Article

    • Google Scholar
40. • Gencer B.
    • Giuglioano R.P.
    • Tang M.
    • Mach F.
    • Stroes E.S.
    • Gouni-Berthold I.
    • et al.
    Clinical safety outcomes in relation to Lipoprotein(a) concentrations: Insights from the FOURIER Trial [abstract].
    Circulation. 2021; 144A11043
    View in Article

    • Google Scholar
41. • O’Donoghue M.L.
    • Fazio S.
    • Giugliano R.P.
    • Stroes E.S.G.
    • Kanevsky E.
    • Gouni-Berthold I.
    • et al.
    Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the FOURIER trial.
    Circulation. 2018; 139: 1483-1492
    View in Article

    • Google Scholar
42. • Bittner V.A.
    • Szarek M.
    • Aylward P.E.
    • Bhatt D.L.
    • Diaz R.
    • Edelberg J.M.
    • et al.
    • ODYSSEY OUTCOMES Committees and Investigators
    Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome.
    J Am Coll Cardiol. 2020; 75: 133-144
    View in Article

    • Google Scholar
43. • Koren M.J.
    • Moriarty P.M.
    • Baum S.J.
    • Neutel J.
    • Hernandez-Illas M.
    • Weintraub H.S.
    • et al.
    Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).
    Nat Med. 2022; 28: 96-103
    View in Article

    • Google Scholar
44. • Nissen S.E.
    • Wolski K.
    • Balog C.
    • Swerdlow D.I.
    • Scrimgeour A.C.
    • Rambaran C.
    • et al.
    Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels.
    Jama. 2022; 327: 1679-1687
    View in Article

    • Google Scholar
45. • Tsimikas S.
    • Karwatowska-Prokopczuk E.
    • Gouni-Berthold I.
    • Tardif J.C.
    • Baum S.J.
    • Steinhagen-Thiessen E.
    • et al.
    AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease.
    N Engl J Med. 2020; 382: 244-255
    View in Article

    • Google Scholar
46. • Reyes-Soffer G.
    The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk.
    Cur Opin Lipidol. 2021; 32: 163-166
    View in Article

    • Google Scholar
47. • de Boer L.M.
    • Hof M.H.
    • Wiegman A.
    • Stroobants A.K.
    • Kastelein J.J.P.
    • Hutten B.A.
    Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic.
    Atherosclerosis. 2022; 349: 227-232
    View in Article

    • Google Scholar
48. • Sofi F.
    • Marcucci R.
    • Abbate R.
    • Gensini G.F.
    • Prisco D.
    Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis.
    Am J Med. 2007; 120: 728-733
    View in Article

    • Google Scholar
49. • Trinder M.
    • Uddin M.M.
    • Finneran P.
    • Aragam K.G.
    • Natarajan P.
    Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease.
    JAMA Cardiol. 2020; 6: 1-9
    View in Article

    • Google Scholar
50. • Watts G.F.
    • Sullivan D.R.
    • Hare D.L.
    • Kostner K.M.
    • Horton A.E.
    • Bell D.A.
    • et al.
    • FH Australasia Network Consensus Working Group
    Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia.
    Heart Lung Circ. 2021; 30: 324-349
    View in Article

    • Google Scholar
51. • Watts G.F.
    • Gidding S.S.
    • Mata P.
    • Pang J.
    • Sullivan D.R.
    • Yamashita S.
    • et al.
    Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.
    Nat Rev Cardiol. 2020; 17: 360-377
    View in Article

    • Google Scholar
52. • Tsimikas S.
    • Fazio S.
    • Ferdinand K.C.
    • Ginsberg H.N.
    • Koschinsky M.L.
    • Marcovina S.M.
    • et al.
    NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis.
    J Am Coll Cardiol. 2018; 71: 177-192
    View in Article

    • Google Scholar
53. • Brouwers M.C.
    • Kerkvliet K.
    • Spithoff K.
    • AGREE Next Steps Consortium
    The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines.
    BMJ. 2016; 352: i1152
    View in Article

    • Google Scholar